{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:32:26Z","timestamp":1790087546111,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.schres.2013.04.002","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T11:50:55Z","timestamp":1368100255000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature"],"prefix":"10.1016","volume":"147","author":[{"given":"Leonardo V.","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2013.04.002_bb0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1176\/appi.ajp.163.2.272","article-title":"Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania","volume":"163","author":"Allen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"5726","key":"10.1016\/j.schres.2013.04.002_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.4.5726.18","article-title":"Correlation of subjective side effects with plasma concentrations of nortriptyline","volume":"4","author":"Asberg","year":"1970","journal-title":"Br. Med. J."},{"issue":"5770","key":"10.1016\/j.schres.2013.04.002_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline","volume":"3","author":"Asberg","year":"1971","journal-title":"Br. Med. J."},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","article-title":"Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors","volume":"21","author":"Balant-Gorgia","year":"1999","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/00048679809068332","article-title":"The clinical use of plasma clozapine levels","volume":"32","author":"Bell","year":"1998","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2013.04.002_bb0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02326373","article-title":"Clozapine plasma level monitoring: current status","volume":"67","author":"Cooper","year":"1996","journal-title":"Psychiatr. Q."},{"issue":"6","key":"10.1016\/j.schres.2013.04.002_bb0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia","volume":"25","author":"Fellows","year":"2003","journal-title":"Ther. Drug Monit."},{"issue":"22","key":"10.1016\/j.schres.2013.04.002_bb0045","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198911303212201","article-title":"Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder","volume":"321","author":"Gelenberg","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF00432736","article-title":"Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects","volume":"74","author":"Hansen","year":"1981","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","article-title":"Elevated levels of clozapine in serum after addition of fluvoxamine","volume":"14","author":"Hiemke","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0924-977X(95)00069-2","article-title":"Fluvoxamine increases the clozapine serum levels significantly","volume":"6","author":"Koponen","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2013.04.002_bb0075","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ps.2010.61.12.1239","article-title":"Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics","volume":"61","author":"Lang","year":"2010","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.schres.2013.04.002_bb0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.schres.2013.04.002_bb0085","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/JCP.0b013e3182356255","article-title":"Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia","volume":"31","author":"Lin","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2013.04.002_bb0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","article-title":"Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response","volume":"31","author":"Lostia","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","article-title":"Clinical outcome and olanzapine plasma levels in acute schizophrenia","volume":"20","author":"Mauri","year":"2005","journal-title":"Eur. Psychiatry"},{"issue":"14","key":"10.1016\/j.schres.2013.04.002_bb0100","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1517\/14656566.8.14.2207","article-title":"Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels","volume":"8","author":"Mauri","year":"2007","journal-title":"Expert. Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.schres.2013.04.002_bb0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00004714-199712000-00006","article-title":"Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients","volume":"17","author":"Perry","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2013.04.002_bb0115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1055\/s-2001-19184","article-title":"Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring","volume":"69","author":"Rao","year":"2001","journal-title":"Fortschr. Neurol. Psychiatr."},{"issue":"8","key":"10.1016\/j.schres.2013.04.002_bb0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","article-title":"Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review","volume":"72","author":"Sparshatt","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.schres.2013.04.002_bb0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.schres.2013.04.002_bb0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1592\/phco.27.1.68","article-title":"Historical review of carbamazepine for the treatment of bipolar disorder","volume":"27","author":"Stoner","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.schres.2013.04.002_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1192\/bjp.171.2.109","article-title":"Pharmacokinetic interactions involving clozapine","volume":"171","author":"Taylor","year":"1997","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2013.04.002_bb0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-199834030-00005","article-title":"The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia","volume":"34","author":"Ulrich","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.schres.2013.04.002_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008571-200303000-00006","article-title":"The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement","volume":"13","author":"van der Weide","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.schres.2013.04.002_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02089958","article-title":"Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline","volume":"14","author":"Vandel","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2013.04.002_bb0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2013.04.002_bb0165","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients","volume":"24","author":"Yasui-Furukori","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2013.04.002_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/JCP.0b013e31822c09a7","article-title":"Comparing the influence of dopamine D(2) polymorphisms and plasma drug concentrations on the clinical response to risperidone","volume":"31","author":"Yasui-Furukori","year":"2011","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413002028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413002028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:04:18Z","timestamp":1645027458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413002028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":34,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0920996413002028"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.04.002","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}